These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 11030834)

  • 1. Anti-inflammatory and healing properties of nerve growth factor in immune corneal ulcers with stromal melting.
    Lambiase A; Bonini S; Aloe L; Rama P; Bonini S
    Arch Ophthalmol; 2000 Oct; 118(10):1446-9. PubMed ID: 11030834
    [No Abstract]   [Full Text] [Related]  

  • 2. Topical Recombinant Human Nerve Growth Factor (Cenegermin) for Neurotrophic Keratopathy: A Multicenter Randomized Vehicle-Controlled Pivotal Trial.
    Pflugfelder SC; Massaro-Giordano M; Perez VL; Hamrah P; Deng SX; Espandar L; Foster CS; Affeldt J; Seedor JA; Afshari NA; Chao W; Allegretti M; Mantelli F; Dana R
    Ophthalmology; 2020 Jan; 127(1):14-26. PubMed ID: 31585826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical application of nerve growth factor on human corneal ulcer.
    Lambiase A; Manni L; Rama P; Bonini S
    Arch Ital Biol; 2003 Mar; 141(2-3):141-8. PubMed ID: 12825325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of nerve growth factor to treat congenital neurotrophic corneal ulceration.
    Tan MH; Bryars J; Moore J
    Cornea; 2006 Apr; 25(3):352-5. PubMed ID: 16633039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of nerve growth factor in surgical wound healing of the cornea.
    Cellini M; Bendo E; Bravetti GO; Campos EC
    Ophthalmic Res; 2006; 38(4):177-81. PubMed ID: 16679804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topical treatment with nerve growth factor for corneal neurotrophic ulcers.
    Baum J
    Surv Ophthalmol; 1999; 43(4):372-3. PubMed ID: 10025520
    [No Abstract]   [Full Text] [Related]  

  • 7. Multilayered amniotic membrane transplantation for severe ulceration of the cornea and sclera.
    Hanada K; Shimazaki J; Shimmura S; Tsubota K
    Am J Ophthalmol; 2001 Mar; 131(3):324-31. PubMed ID: 11239864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of autologous serum eye drops on corneal wound healing after superficial keratectomy in rabbits.
    Akyol-Salman I
    Cornea; 2006 Dec; 25(10):1178-81. PubMed ID: 17172894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The topical application of nerve growth factor as a pharmacological tool for human corneal and skin ulcers.
    Aloe L; Tirassa P; Lambiase A
    Pharmacol Res; 2008 Apr; 57(4):253-8. PubMed ID: 18329283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NGF topical application in patients with corneal ulcer does not generate circulating NGF antibodies.
    Lambiase A; Coassin M; Sposato V; Micera A; Sacchetti M; Bonini S; Aloe L
    Pharmacol Res; 2007 Jul; 56(1):65-9. PubMed ID: 17512750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical treatment with nerve growth factor for neurotrophic keratitis.
    Bonini S; Lambiase A; Rama P; Caprioglio G; Aloe L
    Ophthalmology; 2000 Jul; 107(7):1347-51; discussion 1351-2. PubMed ID: 10889110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor in the topical treatment of traumatic corneal ulcers.
    Scardovi C; De Felice GP; Gazzaniga A
    Ophthalmologica; 1993; 206(3):119-24. PubMed ID: 8272333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of chronic nonhealing neurotrophic corneal epithelial defects with thymosin beta4.
    Dunn SP; Heidemann DG; Chow CY; Crockford D; Turjman N; Angel J; Allan CB; Sosne G
    Ann N Y Acad Sci; 2010 Apr; 1194():199-206. PubMed ID: 20536469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of acetylcysteine on experimental corneal wounds in dogs.
    Aldavood SJ; Behyar R; Sarchahi AA; Rad MA; Noroozian I; Ghamsari SM; Sadeghi-Hashjin G
    Ophthalmic Res; 2003; 35(6):319-23. PubMed ID: 14688421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pilot study of a new matrix therapy agent (RGTA OTR4120) in treatment-resistant corneal ulcers and corneal dystrophy].
    Chebbi CK; Kichenin K; Amar N; Nourry H; Warnet JM; Barritault D; Baudouin C
    J Fr Ophtalmol; 2008 May; 31(5):465-71. PubMed ID: 18641578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of ophthalmic gatifloxacin 0.3% and ciprofloxacin 0.3% in healing of corneal ulcers associated with Pseudomonas aeruginosa-induced ulcerative keratitis in rabbits.
    Jensen H; Zerouala C; Carrier M; Short B
    J Ocul Pharmacol Ther; 2005 Feb; 21(1):36-43. PubMed ID: 15718826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical application of nerve growth factor in human diabetic foot ulcers. A study of three cases.
    Generini S; Tuveri MA; Matucci Cerinic M; Mastinu F; Manni L; Aloe L
    Exp Clin Endocrinol Diabetes; 2004 Oct; 112(9):542-4. PubMed ID: 15505764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical treatment with a new matrix therapy agent (RGTA) for the treatment of corneal neurotrophic ulcers.
    Aifa A; Gueudry J; Portmann A; Delcampe A; Muraine M
    Invest Ophthalmol Vis Sci; 2012 Dec; 53(13):8181-5. PubMed ID: 23150626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Healing of resistant corneal neurotrophic ulcers using a matrix regenerating agent.
    Cochener B; Zagnoli C; Hugny-Larroque C; Derrien S
    J Fr Ophtalmol; 2019 Feb; 42(2):159-165. PubMed ID: 30573293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pediatric Use of Recombinant Human Nerve Growth Factor 20 μg/mL Eye Drops (Cenegermin) for Bilateral Neurotrophic Keratopathy in Congenital Corneal Anesthesia.
    Leto MG; Toro ME; Indemini PE; Fruttero C; Denina M; Dalmazzo C; Sannia A; Vaiano AS
    Cornea; 2021 Feb; 40(2):228-231. PubMed ID: 33201057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.